Complications associated with pegging hydroxyapatite orbital implants
Section snippets
Patients and method
A list of all patients who received a hydroxyapatite orbital implant after evisceration, enucleation, or secondary implantation by two oculoplastic surgeons (DRJ, SG) was obtained. Charts of these patients were reviewed and those patients receiving pegs were identified. These cases were studied, with the following parameters being noted: age, gender, type of surgery, type of implant, time of pegging, type of peg system, problems during the follow-up period, clinical findings, and details
Results
There were 275 cases of hydroxyapatite orbital implantation between May 1990 and March 1997 performed by 2 oculoplastic surgeons (DRJ, 238; SG, 37). Of these, 24 had their implants in place for less than 4 months and were not considered as candidates for the study. Of the remaining 251 patients, 165 (65.7%) received a peg, whereas 86 patients did not. The average age of those patients pegged was 42.4 years (range, 9–75 years). There were 117 males and 48 females in the pegged group. Of those
Discussion
Porous hydroxyapatite has been successfully used as an orbital implant in enucleations, eviscerations, and as secondary implants since 1985.1, 2, 4, 18, 19, 21 In a recent surgery of 5439 intraorbital implants, the hydroxyapatite implant (Bio-Eye) was the one most often used by ophthalmic plastic surgeons in North America.4 With drilling and peg placement, these implants can be directly coupled to the prosthesis, allowing a wide range of prosthetic movement as well as fine darting eye movements
References (26)
Coralline hydroxyapatite as an ocular implant
Ophthalmology
(1991)- et al.
Complications of hydroxyapatite orbital implants. A review of 100 consecutive cases and a comparison of Dexon mesh (polyglycolic acid) with scleral wrapping
Ophthalmology
(1997) - et al.
Management of exposed hydroxyapatite orbital implants
Ophthalmology
(1994) - et al.
Tissue breakdown and exposure associated with orbital hydroxyapatite implants
Am J Ophthalmol
(1992) - et al.
Exposed hydroxyapatite orbital implants. Report of six cases
Ophthalmology
(1992) - et al.
Abscessed hydroxyapatite orbital implants. A report of two cases
Ophthalmology
(1996) - et al.
Hydroxyapatite orbital implant after enucleation — experience with 200 cases
Mayo Clin Proc
(1993) - et al.
Coralline hydroxyapatite spheres as secondary orbital implants in anophthalmos
Ophthalmology
(1995) - et al.
Rate of vascularization of coralline hydroxyapatite ocular implants
Ophthalmology
(1992) - et al.
Role of magnetic resonance imaging in the evaluation of the hydroxyapatite orbital implant
Ophthalmology
(1992)
Advances in enucleation
Ophthal Plast Reconstr Surg
The synthetic hydroxyapatite implanta report on 65 patients
Ophthal Plast Reconstr Surg
Current techniques of enucleationa survey of 5,439 intraorbital implants and a review of the literature
Ophthal Plast Reconstr Surg
Cited by (87)
Porous versus Nonporous Orbital Implants: A 25-Year Retrospective
2018, OphthalmologyOrbital enucleation implants and ocular prostheses: Biocompatibility and design
2016, Biomaterials and Regenerative Medicine in Ophthalmology: Second EditionBioceramics in ophthalmology
2014, Acta BiomaterialiaCitation Excerpt :Less expensive versions of synthetic HA orbital implants have also been developed and are currently in use in some countries; however, they exhibit a number of drawbacks that strongly limit their economic advantage over the other available models. Some of these implants have been reported to contain CaO impurities that, after hydration in host tissues, may form Ca(OH)2, which is caustic [75,76]. Other implants have higher weight, lower porosity (below 50 vol.%) and lower pore interconnectivity than Bio-Eye® and FCI3 implants, with consequent enhanced risk of implant migration and limited fibrovascularization [77].
Biomaterials for orbital implants and ocular prostheses: Overview and future prospects
2014, Acta BiomaterialiaBiphasic mode of antibacterial action of aminoglycoside antibiotics-loaded elastic hydroxyapatite-glucan composite
2013, International Journal of Pharmaceutics